CureVac and BioNTech in the spotlight amid the emerging COVID-19 mutation panic

At the weekend, Great Britain caused a new COVID-19 shock with reports of mutated SARS-CoV-2 viruses, which this morning is burdening the stock exchanges and isolating the “island” more and more. Numerous flight and other travel options to and from Great Britain are suspended until further notice. Meanwhile, two vaccine developers are in the spotlight today, whose means are to become important “weapons” in the fight against the pandemic.

At the moment it is first and foremost BioNTech, whose BNT162 vaccine, developed together with Pfizer, is already approved and administered in Great Britain. The vaccine is said to be equally effective against mutated SARS-CoV-2 viruses – the Mainz-based company had pointed this out earlier. This should also apply to the current mutation. Meanwhile, the approval process for BNT162 in the EU is nearing completion. The European Medicines Agency (EMA) will present an assessment of the vaccine today. The European Commission, which formally issues the approval, should then probably react within a few hours, so that BNT162 could be approved in the EU and used at short notice before Christmas. Nobody expects approval to be rejected.


Related Articles

Back to top button